News: MedPharm, Ltd. Appoints Lynn Allen as Chief Executive Officer
MedPharm, a global topical and transdermal CDMO, announced today that Lynn Allen has been named Chief Executive Officer (CEO), effective January 1, 2024.
Ms. Allen has more than 25 years of experience in contract development and manufacturing services specific to topical, transdermal, and injectable delivery routes. Prior to joining MedPharm in 2019 as Vice President of Business Development, Ms. Allen held a series of commercial leadership roles at DPT Laboratories and Jubilant HollisterStier.
“I am honored to have the opportunity to serve as CEO alongside the expertise and support of the entire leadership team at MedPharm,” said Ms. Allen. “MedPharm’s scientific expertise has consistently proven to be the gold standard in the field of topical and transdermal drug delivery. I look forward to working with our team to continue supporting our customers and successfully execute their drug development programs.”
“We congratulate Lynn on her appointment as CEO as her leadership and deep knowledge of MedPharm’s scientific capabilities, in addition to her strong commercial track record, will be instrumental in MedPharm’s growth and expansion,” added Trevor Wahlbrink, Partner, Ampersand Capital Partners.
MedPharm is a global contract provider of topical and transdermal formulation development services specializing in reducing risk through unique, cost-effective, and industry-leading performance testing models. MedPharm offers innovative dermal/transdermal, respiratory, mucosal membrane, ophthalmic, and ungual product development solutions with locations in the United Kingdom and the United States. For more information, visit MedPharm.com or follow us on LinkedIn